Vasodilator Agents (Vasodilators)

Drugs used to cause dilation of the blood vessels.

Also Known As:

Vasodilators; Vasodilator Drugs; Vasorelaxants; Agent, Vasodilator; Agents, Vasodilator; Antagonists, Vasoactive; Drug, Vasodilator; Drugs, Vasodilator; Vasoactive Antagonists; Vasodilator; Vasodilator Agent; Vasodilator Drug; Vasorelaxant

Networked: 9035 relevant articles (584 outcomes, 885 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Therapeutic Uses: 47080
    - Cardiovascular Agents: 817
      - Vasodilator Agents: 9035
        Endothelium-Dependent Relaxing Factors: 344

Experts

1.	Shimokawa, Hiroaki: 16 articles (02/2021 - 07/2003)
2.	Cardillo, Carmine: 15 articles (12/2021 - 05/2004)
3.	Humbert, Marc: 15 articles (08/2021 - 02/2002)
4.	Mebazaa, Alexandre: 14 articles (12/2019 - 05/2005)
5.	Joyner, Michael J: 14 articles (01/2019 - 03/2004)
6.	Tesauro, Manfredi: 13 articles (12/2021 - 11/2005)
7.	Schinzari, Francesca: 12 articles (12/2021 - 11/2005)
8.	Stauffer, Brian L: 12 articles (12/2021 - 02/2003)
9.	Di Carli, Marcelo F: 12 articles (01/2018 - 10/2002)
10.	Futrakul, Narisa: 12 articles (11/2013 - 01/2002)

Related Diseases

1.	Heart Failure 01/01/1993 - "[Vasodilator agents in chronic heart failure: which is the best option?]." 05/01/1992 - "Thus, intravenous bolus injection of ISDN showed a potent vasodilator effects on preload, and may be a safe and useful treatment for aged patients with acute congestive heart failure." 04/01/1991 - "Potent new inotropic vasodilators have improved ventricular performance but have not prolonged life in patients with end-stage heart failure. " 01/01/1994 - "The purpose of this review is to discuss some of these trials and to describe the answers that they provide to the following questions: Are vasodilators beneficial in the treatment of severe heart failure? " 09/01/1994 - "On the surface, progress in development of vasodilators and inotropic agents for heart failure has been successful, but the average improved survival time is only about 9 to 18 months. "
2.	Pulmonary Hypertension 01/01/2018 - "Although pulmonary vasodilators are effective for Group 1 pulmonary hypertension, clinical guidelines and the Choosing Wisely Campaign recommend against routine use for Groups 2 and 3 pulmonary hypertension (the most common types of pulmonary hypertension) because of a lack of benefit, potential for harm, and high cost ($10,000-$13,000 per patient per year treated). " 03/01/2009 - "More evidence is required to resolve whether vasodilator treatments are beneficial for inoperable chronic thromboembolic pulmonary hypertension." 01/01/1997 - "During NO inhalation patients demonstrated a statistically significant reduction in systolic pulmonary arterial pressure by approximately 26%; from 55 +/- 10 to 41 +/- 20 mm Hg. Inhalation of NO resulted in a significant increase of Pao2 from 110 +/- 16 to 149 +/- 29 mm Hg. A-aDo2 significantly decreased from 284 +/- 27 to 247 +/- 31 mm Hg. In conclusion, we have shown that a low-dose NO inhalation acted as pulmonary vasodilator in patients with preexisting pulmonary hypertension." 01/01/2003 - "Vasodilators may be more effective in reducing pulmonary hypertension in females than in males." 08/15/1999 - "It is effective in the acute post-operative management of pulmonary hypertension in cardiac surgical patients and is also valuable in assessing the pulmonary vasodilator capacity in patients with chronic pulmonary hypertension. "
3.	Hypertension (High Blood Pressure) 01/01/1984 - "This new vasodilator proved highly effective in the treatment of severe hypertension. " 01/01/1982 - "Vasodilators are highly efficacious in hypertension and the ideal one(s) have not yet been developed. " 12/15/2022 - "Inhaled NO is a selective pulmonary vasodilator proven to be therapeutic for patients with pulmonary artery hypertension (PAH). " 10/01/2004 - "A significantly greater number in this group required the use of a vasodilator to control intraoperative hypertension." 04/15/1985 - "Vasodilator drugs are effective in the treatment of the whole range of hypertensive diseases, from severe refractory hypertension to mild hypertension. "
4.	Ischemia 01/01/1996 - "Since alcohol is a vasodilator, we postulated that it might have protective effects when administered acutely in the setting of ischemia/reperfusion. " 01/01/2022 - "327 women with INOCA enrolled in the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction (WISE-CVD) study underwent vasodilator stress cardiac magnetic resonance imaging (CMRI) and u-hscTnI measurements (Simoa HD-1 Analyzer, Quanterix Corporation). " 01/01/2021 - "The objectives of this study were to evaluate the agreement between RFR and FFR with the currently recommended thresholds and to design a hybrid RFR-FFR ischemia detection strategy, allowing a reduction of coronary vasodilator use. " 10/15/2020 - "Additionally, the role of remote ischemia preconditioning and vasodilators in the prevention of contrast-induced nephropathy needs further study. " 05/01/2015 - "The present study aimed to investigate the effects of ligustrazin, which has a vasodilator impact on intestinal ischemia. "
5.	Hypoxia (Hypoxemia) 06/01/1998 - "In conclusion, chronic hypoxia resulted in a significant depolarization in small pulmonary arteries, but this may explain only partly the increased efficacy of voltage-dependent vasodilators. " 10/01/1982 - "In all the subjects in whom HPV was partially inhibited by vasodilator administration, the alveolar-arterial PO2 gradients remained significantly lowered, suggesting that the pulmonary vascular tone adaptation to alveolar hypoxia still was effective in improving ventilation/perfusion relationships. " 04/01/2013 - "Alleviation of HPV and HPH via vasodilators has been shown to improve blood oxygen saturation and exercise performance in hypoxia. " 01/01/2006 - "Nonetheless, the vasodilator efficacy of NO is enhanced in hypoxic arteries, which suggests that mechanisms downstream from sGC are upregulated by hypoxia. " 11/02/2022 - "Further, a trial of pulmonary vasodilators is suggested for those who develop refractory hypoxemia. "

Related Drugs and Biologics

1.	Diuretics
2.	Nitric Oxide (Nitrogen Monoxide)
3.	Hydralazine (Apresoline)
4.	Vasodilator Agents (Vasodilators)
5.	Epoprostenol (Prostacyclin)
6.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
7.	Calcium Channel Blockers (Blockers, Calcium Channel)
8.	Antihypertensive Agents (Antihypertensives)
9.	Nitrates
10.	Antioxidants

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Percutaneous Coronary Intervention
4.	Heart Transplantation (Grafting, Heart)
5.	Transplantation